Tuberculosis vaccine H4IC - Valneva/AJ Vaccines

Drug Profile

Tuberculosis vaccine H4IC - Valneva/AJ Vaccines

Alternative Names: Adjuvanted TB subunit vaccine H4IC - Valneva/sanofi pasteur/AJ Vaccines; AERAS-404; Ag85B-TB10.4-IC31; H4+IC31; H4/AERAS-404+IC31®; H4/IC31 vaccine; H4:IC31; HyVac4; HyVac4-IC31; Tuberculosis vaccine H4IC - Valneva/sanofi pasteur/AJ Vaccines

Latest Information Update: 19 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Statens Serum Institut
  • Developer Aeras; AJ Vaccines; National Institute of Allergy and Infectious Diseases; Sanofi Pasteur; Statens Serum Institut
  • Class Adjuvants; Antituberculars; Recombinant fusion proteins; Subunit vaccines; Synthetic vaccines; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Tuberculosis

Most Recent Events

  • 06 Oct 2017 Aeras completes a phase II trial in Tuberculosis (Prevention, In adolescents) in South Africa (NCT02075203)
  • 21 Sep 2017 Tuberculosis vaccine H4IC is still in phase I/II trials for Tuberculosis (Prevention, In infants) in South Africa (NCT01861730)
  • 21 Sep 2017 Tuberculosis vaccine H4IC is still in phase II trials for Tuberculosis (Prevention, In adolescents) in South Africa (NCT02075203)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top